About Boston Scientific
Boston Scientific pioneered the development of minimally invasive medical devices and has been transforming the way conditions are diagnosed and treated for more than four decades. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company has grown into one of the world's largest medical device manufacturers, listed on the New York Stock Exchange under the ticker BSX.
Cardiology & Electrophysiology
Cardiac care sits at the core of Boston Scientific's portfolio. The company is widely recognised for its electrophysiology technologies, including mapping and ablation systems used to treat cardiac arrhythmias, as well as transcatheter heart valves, stents, and heart failure management devices. Its WATCHMAN device, designed to reduce stroke risk in patients with non-valvular atrial fibrillation by closing the left atrial appendage, has become one of its most prominent commercial products globally.
Endoscopy, Urology & Neuromodulation
Beyond cardiology, Boston Scientific holds strong positions in endoscopy, offering a broad range of tools for gastrointestinal diagnosis and intervention, and in urology and pelvic health, where it provides stone management, benign prostatic hyperplasia treatment, and incontinence solutions. Its neuromodulation division manufactures spinal cord stimulation and deep brain stimulation systems, addressing chronic pain and movement disorders such as Parkinson's disease.
The company operates across more than 100 countries, with a substantial manufacturing and research presence in the United States, Europe, and Asia. Boston Scientific employs tens of thousands of people worldwide and invests heavily in research and development each year, sustaining a pipeline that spans structural heart, peripheral interventions, oncology, and cardiac rhythm management.
Acquisitions have been central to its growth strategy, with notable deals including the purchase of Guidant Corporation and, more recently, Silk Road Medical and Acotec Scientific, expanding its reach into carotid artery disease and peripheral vascular intervention respectively.
Further information is available at bostonscientific.com.
